What can we help you find?

Leading the way in transplantation

Filter results for:

New resource available on Transplant Live: Management of CMV in solid organ transplant recipients

We are pleased to announce that our latest workshop, titled “Managing CMV in Solid Organ Transplant Recipients” is now available on ESOT Transplant Live [when in Transplant Live please go to Courses]. This educational programme aims to enhance the management of Cytomegalovirus (CMV) infections among transplant recipients, which can pose a significant challenge post-surgery. The

ESOT Masterclass Now Accepting Applications!

Aimed at young professional working in solid organ transplant, this Masterclass will provide crucial insight into the cutting-edge technologies that are about to revolutionise the transplantation field, including cell-free DNA, new plasma, urinary and immune function biomarkers, gene-expression profiling, as well as recent advances on HLA and non-HLA antibodies.

ECTTA Call for nominations

ECTTA, The European Cardio Thoracic Transplant Section of ESOT, would like to announce a call for two new Board members. The new ECTTA Board Members will hold office for four years (2023-2027), starting at the ESOT Congress, September 2023. All ESOT/ECTTA affiliates are eligible to submit their applications for the positions. You may nominate yourself

ECTTA Call for Nominations

We would like to announce a call for nominations for five new Board members.  All ESOT/ ECTTA affiliates are welcome to send applications for these positions. The new ECTTA Board Members will hold office for 4 years (2021-2025). ECTTA is the scientific forum to experience exchange on treatment of patients with end-stage heart and lung

ESOT multi-organ registry

On March 5th 2021, ESOT opened a tender for a technical provider that will build the multi-organ registry. ESOT is seeking the support of additional European national authorities and expect to finalise agreement with participating countries by the end of April 2021. In addition, ESOT is establishing contacts with non-European countries and registries. read more

The COVID-19 Vaccine Studies

Transplant patients are exceptionally vulnerable to all infections, especially COVID-19, due to immunosuppression and other co-morbidities. There is a clear need for these patients to receive the best available protection against COVID-19 and we strongly believe that they should be considered as a priority group for vaccination across Europe. Furthermore, our patients and the broader